These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37853236)

  • 1. Quantitative analysis of pre-treatment dynamic contrast-enhanced ultrasound for assessing the response of colorectal liver metastases to chemotherapy plus targeted therapy: a dual-institutional study.
    Zhou BY; Liu H; Pu YY; Wang LF; Sun YK; Yin HH; Lu D; Ye X; Hu XY; Wang X; Han H; Xia HS; Zhao CK; Xu HX
    Abdom Radiol (NY); 2024 Feb; 49(2):414-424. PubMed ID: 37853236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy.
    Ravanelli M; Agazzi GM; Tononcelli E; Roca E; Cabassa P; Baiocchi G; Berruti A; Maroldi R; Farina D
    Radiol Med; 2019 Sep; 124(9):877-886. PubMed ID: 31172448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early evaluation of liver metastasis using spectral CT to predict outcome in patients with colorectal cancer treated with FOLFOXIRI and bevacizumab.
    Li S; Yuan L; Yue M; Xu Y; Liu S; Wang F; Liu X; Wang F; Deng J; Sun Q; Liu X; Xue C; Lu T; Zhang W; Zhou J
    Cancer Imaging; 2023 Mar; 23(1):30. PubMed ID: 36964617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response evaluation of chemotherapy in metastatic colorectal cancer by contrast enhanced ultrasound.
    Schirin-Sokhan R; Winograd R; Roderburg C; Bubenzer J; do Ó NC; Guggenberger D; Hecker H; Trautwein C; Tischendorf JJ
    World J Gastroenterol; 2012 Feb; 18(6):541-5. PubMed ID: 22363120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer.
    Amadori M; Barone D; Scarpi E; Oboldi D; Amadori E; Bandi G; Rossi A; Ferroni F; Ragazzini A; Casadei Gardini A; Frassineti GL; Gavelli G; Passardi A
    Eur Radiol; 2018 Jul; 28(7):2969-2978. PubMed ID: 29417252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trial.
    Mazard T; Mollevi C; Loyer EM; Léger J; Chautard R; Bouché O; Borg C; Armand-Dujardin P; Bleuzen A; Assenat E; Lecomte T
    Cancer Imaging; 2024 Jun; 24(1):77. PubMed ID: 38886836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced Rim on MDCT of Colorectal Liver Metastases: Assessment of Ability to Predict Progression-Free Survival and Response to Bevacizumab-Based Chemotherapy.
    Cheng J; Qiu M; Zhang Y; Hong N; Shen D; Zhou J; Wang Y
    AJR Am J Roentgenol; 2020 Dec; 215(6):1377-1383. PubMed ID: 32991216
    [No Abstract]   [Full Text] [Related]  

  • 8. Deep radiomics-based fusion model for prediction of bevacizumab treatment response and outcome in patients with colorectal cancer liver metastases: a multicentre cohort study.
    Zhou S; Sun D; Mao W; Liu Y; Cen W; Ye L; Liang F; Xu J; Shi H; Ji Y; Wang L; Chang W
    EClinicalMedicine; 2023 Nov; 65():102271. PubMed ID: 37869523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
    Bond MJG; Bolhuis K; Loosveld OJL; de Groot JWB; Droogendijk H; Helgason HH; Hendriks MP; Klaase JM; Kazemier G; Liem MSL; Rijken AM; Verhoef C; de Wilt JHW; de Jong KP; Gerhards MF; van Amerongen MJ; Engelbrecht MRW; van Lienden KP; Molenaar IQ; de Valk B; Haberkorn BCM; Kerver ED; Erdkamp F; van Alphen RJ; Mathijssen-van Stein D; Komurcu A; Lopez-Yurda M; Swijnenburg RJ; Punt CJA;
    Lancet Oncol; 2023 Jul; 24(7):757-771. PubMed ID: 37329889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying response in colorectal liver metastases treated with bevacizumab: development of RECIST by combining contrast-enhanced and diffusion-weighted MRI.
    Liu LH; Zhou GF; Lv H; Wang ZC; Rao SX; Zeng MS
    Eur Radiol; 2021 Aug; 31(8):5640-5649. PubMed ID: 33449175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy.
    Mazard T; Assenat E; Dupuy M; Mollevi C; René A; Adenis A; Chauffert B; Boucher E; Francois E; Pierga JY; Ducreux M; Ychou M; Gallix B
    Dig Liver Dis; 2019 Aug; 51(8):1185-1191. PubMed ID: 31085108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VueBox® perfusion analysis of dynamic contrast enhanced ultrasound provides added value in the diagnosis of small thyroid nodules.
    Huang Y; Wang Y; Liu L; Zhu L; Qiu Y; Zuo D; Lu X; Dong Y; Jung EM; Wang W
    Clin Hemorheol Microcirc; 2023; 83(4):409-420. PubMed ID: 36683500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
    Dohan A; Gallix B; Guiu B; Le Malicot K; Reinhold C; Soyer P; Bennouna J; Ghiringhelli F; Barbier E; Boige V; Taieb J; Bouché O; François E; Phelip JM; Borel C; Faroux R; Seitz JF; Jacquot S; Ben Abdelghani M; Khemissa-Akouz F; Genet D; Jouve JL; Rinaldi Y; Desseigne F; Texereau P; Suc E; Lepage C; Aparicio T; Hoeffel C;
    Gut; 2020 Mar; 69(3):531-539. PubMed ID: 31101691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy.
    Arita J; Ono Y; Takahashi M; Inoue Y; Takahashi Y; Saiura A
    Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S390-7. PubMed ID: 24570378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
    Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
    Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy - a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol.
    Boilève A; Maillard A; Wagner M; Dromain C; Laurent C; Dupont Bierre E; Le Sourd S; Audemar F; Ulusakarya A; Guerin-Meyer V; Smisth D; Pezzella V; De Baere T; Goere D; Gelli M; Taieb J; Boige V
    BMC Cancer; 2020 Jan; 20(1):74. PubMed ID: 32000724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Perioperative Chemotherapies for Patients with Colorectal Liver Metastasis].
    Okazaki S; Ishikawa T; Uetake H
    Gan To Kagaku Ryoho; 2020 Apr; 47(4):574-577. PubMed ID: 32389954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dynamic Contrast-enhanced Magnetic Resonance Imaging Permeability Parameters Monitor the Early Response to Bevacizumab Plus Chemotherapy in Colorectal Cancer Patients with Liver Metastases].
    Liu D; Qian HF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Apr; 40(2):256-263. PubMed ID: 29724317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases.
    Creasy JM; Midya A; Chakraborty J; Adams LB; Gomes C; Gonen M; Seastedt KP; Sutton EJ; Cercek A; Kemeny NE; Shia J; Balachandran VP; Kingham TP; Allen PJ; DeMatteo RP; Jarnagin WR; D'Angelica MI; Do RKG; Simpson AL
    Eur Radiol; 2019 Jan; 29(1):458-467. PubMed ID: 29922934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.